Merck and ISB Collaborate to Understand and Treat SARS-CoV-2 Infection
heath.isbscience.org/2020/04/27/merck-isb-covid/
heath.isbscience.org/2020/04/27/merck-isb-covid/ Recent Articles
-
ISB Builds Digital Platform for COVID-19 Research Study – and Beyond
In a multi-institutional study of a highly infectious disease like COVID-19, paperless consent for study participants is critical. One component of the COVID-19 Immune Response Study is a recruitment website with an IRB-approved and HIPAA-compliant electronic consent platform for enrolling patients.
-
For Cancer Cells, There Is More Than One Path to Drug Resistance
In findings published in the journal Nature Communications, researchers show that cancer cells can take more than one path to reach a drug-resistant cell state. These findings could have promising implications for the future of cancer care.
-
Merck, ISB, Swedish Collaborate In Trial to Understand, Treat COVID-19
ISB and Swedish Medical Center launched a study to follow hundreds of patients who contract COVID-19 to learn why those infected have drastically different outcomes. “Each of the COVID-19 patients has a unique lesson to teach us about how the medical and scientific community can respond most effectively to this pandemic,” said ISB President Dr. Jim Heath, who co-leads the study.